The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Rational Design of a Combination Medication for the Treatment of Obesity
Open accessAbstract
Existing obesity therapies are limited by safety concerns and modest efficacy reflecting a weight loss plateau. Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction. In vitro electrophysiologic experiments were conducted to determine the extent to which BUP+NAL stimulated hypothalamic pro‐opiomelanocortin (POMC) neurons in mouse brain. A subsequent study further characterized the effect of combination BUP+NAL treatment on food intake in lean and obese mice. Finally, a randomized, blinded, placebo‐controlled trial in obese adult subjects was conducted. Randomization included: BUP (300 mg) + NAL (50 mg), BUP (300 mg) + placebo (P), NAL (50 mg) + P or P+P for up to 24 weeks. BUP+NAL stimulated murine POMC neurons in vitro and caused a greater reduction in acute food intake than either monotherapy, an effect consistent with synergism. Combined BUP+NAL provided sustained weight loss without evidence of an efficacy plateau through 24 weeks of treatment. BUP+NAL completers diverged from NAL+P (P < 0.01) and P+P (P < 0.001) at week 16 and from BUP+P by week 24 (P < 0.05). The combination was also well tolerated. Translational studies indicated that BUP+NAL therapy produced synergistic weight loss which exceeded either BUP or NAL alone. These results supported the hypothesis that NAL, through blockade of β‐endorphin mediated POMC autoinhibition, prevents the classic weight loss plateau observed with monotherapies such as BUP. This novel treatment approach (BUP+NAL) holds promise for the treatment of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Overweight and Obesity in the United States, 1999-2004
Ogden, C. L., Carroll, M. D., Curtin, L. R., McDowell, M. A., Tabak, C. J., & Flegal, K. M. (2006) · JAMA · doi:10.1001/jama.295.13.1549 · Cited by 8,720
Actual causes of death in the United States
McGinnis, J. M. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510180077038 · Cited by 5,480
Actual Causes of Death in the United States, 2000
Mokdad, A. H. (2004) · JAMA · doi:10.1001/jama.291.10.1238 · Cited by 5,211
Prevalence of Overweight and Obesity in the United States
Crespo, C. J., & Ellen, S. (2003) · Obesity: Etiology Assessment Treatment and Prevention · doi:10.5040/9781718206601.ch-001 · Cited by 4,379
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Self-citationRole of melanocortinergic neurons in feeding and the agouti obesity syndrome
Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J., & Cone, R. D. (1997) · Nature · doi:10.1038/385165a0 · Cited by 1,902
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Anatomy and regulation of the central melanocortin system
Cone, R. D. (2005) · Nature Neuroscience · doi:10.1038/nn1455 · Cited by 1,583
Cause-Specific Excess Deaths Associated With Underweight, Overweight, and Obesity
Flegal, K. M., Graubard, B. I., Williamson, D. F., & Gail, M. H. (2007) · JAMA · doi:10.1001/jama.298.17.2028 · Cited by 1,542
Lignac, G. O. E. (1951) · PubMed · Cited by 1,013
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Self-citationSLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Apovian, C. M., Aronne, L., Rubino, D., Still, C., Wyatt, H., Burns, C., Kim, D., Dunayevich, E., & for the COR‐II Study Group (2013) · Obesity · doi:10.1002/oby.20309 · Cited by 720
Self-citationCellular bioenergetics as a target for obesity therapy
Tseng, Y.-H., Cypess, A. M., & Kahn, C. R. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3138 · Cited by 591
The effects of opioids and opioid analogs on animal and human endocrine systems
Vuong, C., Van Uum, S. H. M., O'Dell, L. E., Lutfy, K., & Friedman, T. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0009 · Cited by 564
Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi‐Sunyer, F. X., Rock, C. L., Erickson, J. S., et al. (2011) · Obesity · doi:10.1038/oby.2010.147 · Cited by 558
Self-citationHollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care · doi:10.2337/dc13-0234 · Cited by 501
Self-citationAnti-obesity drugs: past, present and future
Rodgers, R. J., Tschöp, M. H., & Wilding, J. P. H. (2012) · Disease Models & Mechanisms · doi:10.1242/dmm.009621 · Cited by 430
Current pharmacotherapy for obesity
Srivastava, G., & Apovian, C. M. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.122 · Cited by 397
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Grunvald, E., Shah, R., Hernaez, R., Chandar, A. K., Pickett-Blakely, O., Teigen, L. M., Harindhanavudhi, T., Sultan, S., Singh, S., & Davitkov, P. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.08.045 · Cited by 347
GLP-1 and weight loss: unraveling the diverse neural circuitry
Kanoski, S. E., Hayes, M. R., & Skibicka, K. P. (2016) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00520.2015 · Cited by 290
Nissen, S. E., Wolski, K. E., Prcela, L., Wadden, T., Buse, J. B., Bakris, G., Perez, A., & Smith, S. R. (2016) · JAMA · doi:10.1001/jama.2016.1558 · Cited by 273
Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1350 · Cited by 179
Self-citationCentrally Acting Agents for Obesity: Past, Present, and Future
Coulter, A. A., Rebello, C. J., & Greenway, F. L. (2018) · Drugs · doi:10.1007/s40265-018-0946-y · Cited by 151
Self-citationLatest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
Medical treatment of obesity: The past, the present and the future
Bray, G. A. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.015 · Cited by 109
Update on obesity pharmacotherapy
Bray, G. A., & Ryan, D. H. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12328 · Cited by 88
The role of craving in emotional and uncontrolled eating
Verzijl, C. L., Ahlich, E., Schlauch, R. C., & Rancourt, D. (2018) · Appetite · doi:10.1016/j.appet.2017.12.014 · Cited by 79
(2016) · PubMed Central · Cited by 77
The limits and challenges of antiobesity pharmacotherapy
Gadde, K. M., & Atkins, K. D. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1748599 · Cited by 65
Self-citationThe new era of drug therapy for obesity: the evidence and the expectations
Jones, B. J., & Bloom, S. R. (2015) · Drugs · doi:10.1007/s40265-015-0410-1 · Cited by 58
Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Nutritional implications of opioid use disorder: A guide for drug treatment providers
Chavez, M. N., & Rigg, K. K. (2020) · Psychology of Addictive Behaviors · doi:10.1037/adb0000575 · Cited by 38
Combination phentermine and topiramate extended release in the management of obesity.
Alfaris, N., Minnick, A. M., Hopkins, C. M., Berkowitz, R. I., & Wadden, T. A. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041505 · Cited by 38
Lyu, X., Du, J., Zhan, G., Wu, Y., Su, H., Zhu, Y., Jarskog, F., Zhao, M., & Fan, X. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00181 · Cited by 27
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
The role of anti-obesity medication in prevention of diabetes and its complications
Oh, T. J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.3.158 · Cited by 19
How to apply the Canadian Obesity Clinical Practice Guidelines to people with type 2 diabetes
Pedersen, S. D. (2023) · Canadian Diabetes & Endocrinology Today · doi:10.58931/cdet.2023.115 · Cited by 1
Metadata
- Authors
- Greenway, F. L., Whitehouse, M. J., Guttadauria, M., Anderson, J. W., Atkinson, R. L., Fujioka, K., Gadde, K. M., Gupta, A. K., O'Neil, P., Schumacher, D., Smith, D., Dunayevich, E., Tollefson, G. D., Weber, E., & Cowley, M. A.
- Venue
- Obesity
- Publisher
- Wiley
- Published
- 2009-01
- Volume
- 17
- Issue
- 1
- Pages
- 30-39
- ISSN
- 1930-7381 (ISSN-L)
- 1930-739X
- OpenAlex
- W2144589456
- Cited by
- 345
- References
- 47
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.